NetworkNewsBreaks – Odyssey Health Inc. (ODYY) S
Post# of 85
(Total Views: 156)
Posted On: 06/24/2022 4:27:16 PM
NetworkNewsBreaks – Odyssey Health Inc. (ODYY) Sets Sights on US Phase II Clinical Trials with Focus on Military
Odyssey Health (OTC: ODYY) understands the severity of concussions among service members as well as the existing gaps in treatment. The Center for Disease Control (“CDC”) reports that over 430,000 military service members were diagnosed with traumatic brain injury (“TBI”) between 2000 and 2020, with 75-83% of the cases being categorized as mild (“mTBI”) or concussion. And though concussion greatly impacts military service members, there is insufficient evidence supporting, among other things, the optimal treatment strategies to mitigate these impacts. “Odyssey Health is working to develop treatments for concussion and other neurological disorders. Odyssey is developing the PRV-002, a novel, fully synthetics, non-naturally occurring neurosteroid for the treatment of concussion that is the subject of ongoing phase I clinical trials,” reads a recent article. “Data from a recently completed safety evaluation of cohort I revealed that PRV-002 is well-tolerated, meaning no severe adverse events were noted. Encouraged by the positive results from the preclinical and the ongoing phase I study, Odyssey has set sights on phase II clinical trials in the U.S., which will initially focus on the military.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Odyssey Health (OTC: ODYY) understands the severity of concussions among service members as well as the existing gaps in treatment. The Center for Disease Control (“CDC”) reports that over 430,000 military service members were diagnosed with traumatic brain injury (“TBI”) between 2000 and 2020, with 75-83% of the cases being categorized as mild (“mTBI”) or concussion. And though concussion greatly impacts military service members, there is insufficient evidence supporting, among other things, the optimal treatment strategies to mitigate these impacts. “Odyssey Health is working to develop treatments for concussion and other neurological disorders. Odyssey is developing the PRV-002, a novel, fully synthetics, non-naturally occurring neurosteroid for the treatment of concussion that is the subject of ongoing phase I clinical trials,” reads a recent article. “Data from a recently completed safety evaluation of cohort I revealed that PRV-002 is well-tolerated, meaning no severe adverse events were noted. Encouraged by the positive results from the preclinical and the ongoing phase I study, Odyssey has set sights on phase II clinical trials in the U.S., which will initially focus on the military.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)